drugset / Trial / NCT01671072

Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

NCT01671072 ↗

Phase 2 Completed 54 enrolled Kolon Life Science
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether TissueGene-C, an allogeneic human chondrocytes expressing Transforming Growth Factor(TGF)-b1, is effective and safe in patients with degenerative arthritis

Timeline

Start
2011-07
Primary completion
2012-10
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TissueGene-C Cell therapy 1.8e+07 cells Other

Indications